Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients.

Autor:	Cury PCC; Faculdade de Ciências Médicas da Santa Casa de São Paulo (FCMSCSP), São Paulo, SP, Brazil; Clínica São Germano São Paulo, SP, Brazil. Electronic address: pricury@yahoo.com., Higashi F; Faculdade de Ciências Médicas da Santa Casa de São Paulo (FCMSCSP), São Paulo, SP, Brazil; Clínica São Germano São Paulo, SP, Brazil., Zacchi FFS; Laboratório Fleury, São Paulo, SP, Brazil., Palhares RB; Instituto de infectologia Emílio Ribas, São Paulo, SP, Brazil., Quero AA; Faculdade de Ciências Médicas da Santa Casa de São Paulo (FCMSCSP), São Paulo, SP, Brazil., Dias ALMS; Faculdade de Ciências Médicas da Santa Casa de São Paulo (FCMSCSP), São Paulo, SP, Brazil., Crusoé EQ; Universidade da Bahia (UFBA), Salvador, BA, Brazil; Clínica CEHON Rede oncologia D'or, Salvador, BA, Brazil., Hungria VTM; Faculdade de Ciências Médicas da Santa Casa de São Paulo (FCMSCSP), São Paulo, SP, Brazil; Clínica São Germano São Paulo, SP, Brazil.
Jazyk:	angličtina
Zdroj:	Hematology, transfusion and cell therapy [Hematol Transfus Cell Ther] 2020 Apr - Jun; Vol. 42 (2), pp. 159-163. Date of Electronic Publication: 2019 Aug 10.
DOI:	10.1016/j.htct.2019.04.006
Abstrakt:	Background: Bone marrow angiogenesis is increased in multiple myeloma (MM) patients, prompting the rationale for using antiangiogenic drugs in the treatment of these patients. Objective: To assess angiogenesis in patients with MM at diagnosis and following treatment with an antiangiogenic drug. Patients and Methods: Twenty-three patients with newly diagnosed MM were treated with thalidomide-based regimens. Bone marrow evaluation was made before and following treatment and included angiogenesis assessment, which was quantified through microvessel density (MVD) determination, by means of anti-CD34 immunohistochemical labeling, and classified either as high MVD or low MVD, according to the mean CD34 count: above or below the median of 12.6. Results: The pre-therapy median MVD was 12 (7.5-18.3) versus 8.7 (5.35-18.5) post-therapy, p=0.2114. Conclusions: Our study found no reduction in MVD before and following treatment and, accordingly, we could establish no relationship between MVD and response to therapy in the sample we studied. (Copyright © 2020 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu